SideKicker (@sidekicker200) 's Twitter Profile
SideKicker

@sidekicker200

I Don know wat Im doin

ID: 1352742494996459520

calendar_today22-01-2021 22:18:51

7,7K Tweet

1,1K Takipçi

1,1K Takip Edilen

Jason | Growth Advisor (@growthadvisorhq) 's Twitter Profile Photo

Just a reminder that $HIMS has been valued at a 30 P/S multiple in the past 🤯 My target of 20 P/S may be too low! On 2025 revs of $3B we are looking at a $90B MC. That's a 10x from here to $400+/share 🚀

Just a reminder that $HIMS has been valued at a 30 P/S multiple in the past 🤯

My target of 20 P/S may be too low!

On 2025 revs of $3B we are looking at a $90B MC. That's a 10x from here to $400+/share 🚀
Tech Investor (@tech_investor20) 's Twitter Profile Photo

$HIMS popularity chart over 5 years is at all time highs. This popularity is not because of Super Bowl Ad but a natural response to the company fast growing business.

$HIMS popularity chart over 5 years is at all time highs. This popularity is not because of Super Bowl Ad but a natural response to the company fast growing business.
mon (@moninvestor) 's Twitter Profile Photo

$HIMS reminds me of $NFLX in its early days. When Netflix first started, it didn’t invent anything new—it simply repackaged existing products in a more convenient way. DVDs already existed, and so did movie rentals, but Netflix took that model and made it better, more

Oguz O. | 𝕏 Capitalist 💸 (@thexcapitalist) 's Twitter Profile Photo

$HIMS is still a 10x opportunity from here. It's printing cash, expanding product line and launching into the home care market. Here is my full investment thesis: 🧵

$HIMS is still a 10x opportunity from here.

It's printing cash, expanding product line and launching into the home care market.

Here is my full investment thesis: 🧵
Antonio Linares (@alc2022) 's Twitter Profile Photo

I believe that the $40K extra I just chipped into $HIMS will be worth ~$120K soon. The fundamentals are looking stronger than when the stock hit $72.

The Long Investor (@thelonginvest) 's Twitter Profile Photo

I don’t know what was more stupid from the Street In May 2024 when $HIMS dropped to $11 because of a tweet Or Feb 2025 when $HIMS reported +95% Revenue Growth and +50% guidance increase and the share price dropped -29% After both scenarios we added And after the first

Antonio Linares (@alc2022) 's Twitter Profile Photo

If you liked $HIMS at $70 you should love it at $40. The stock is up 100% since October and the fundamentals are excellent, but people panic because of a mini correction. Stomach > brain

Antonio Linares (@alc2022) 's Twitter Profile Photo

Revenue up 95% YoY. Expected to grow 53% in 2025, excluding GLP-1, with a majority of weight loss revenue coming from oral and liraglutide offerings. Perfect execution. Perfect fundamentals. Awesome cash flow. Infinite runway. $HIMS is trading a 3.6 times forward sales.

Dave (@eventuallywlthy) 's Twitter Profile Photo

I started buying $HIMS in the $8s & a couple days ago we nearly touched $80 before dropping to $36 I took a day to reflect on the earnings & clear out some emotions Here’s my reaction to the report (deep dive thread) 🧵

I started buying $HIMS in the $8s & a couple days ago we nearly touched $80 before dropping to $36

I took a day to reflect on the earnings & clear out some emotions

Here’s my reaction to the report (deep dive thread) 🧵
Nate Endicott (@endicottinvests) 's Twitter Profile Photo

I think $HIMS is the most obvious play in the market right now. Going to highlight all of the DD I have been compiling these last few weeks. Prepare for a longer post. Why I think $HIMS is set to become the modern day healthcare platform 1. Let's start off with

I think $HIMS is the most obvious play in the market right now.    

Going to highlight all of the DD I have been compiling these last few weeks. Prepare for a longer post.   

Why I think $HIMS is set to become the modern day healthcare platform   

1. Let's start off with
M. V. Cunha (@mvcinvesting) 's Twitter Profile Photo

amit Here's the reason IMO: The main bear case for short sellers has centered around litigation risk. In previous quarters, Andrew Dudum was firm about continuing to sell compounded GLP-1s even after the shortage ended, by personalizing dosages in a way that, allegedly, wouldn't